ZYVERSA THERAPEUTICS, INC. Deferred Costs, Noncurrent
ZYVERSA THERAPEUTICS, INC. (ZVSA) had Deferred Costs, Noncurrent of $44.73 thousand as of 2025-09-30, per its 10-Q filed 2025-11-19.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredCosts · last filed 2026-03-31
- 2025-09-30: Deferred Costs, Noncurrent $44.73K.
- 2025-06-30: Deferred Costs, Noncurrent $374.66K.
- 2025-03-31: Deferred Costs, Noncurrent $48.85K.
- 2024-12-31: Deferred Costs, Noncurrent $57.24K.
| Period end | Deferred Costs, Noncurrent |
|---|---|
| 2025-09-30 | $44.73K 10-Q · filed 2025-11-19 |
| 2025-06-30 | $374.66K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $48.85K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $57.24K 10-K · filed 2026-03-31 |
| 2024-09-30 | $207.13K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |